Johnson & Johnson announced on Monday that it has submitted a request to the U.S. Food and Drug Administration (FDA) to expand the use of its ketamine-based medication, Spravato, as a standalone treatment for individuals with treatment-resistant depression. This move aims to offer new hope to patients who struggle with this challenging condition.
Spravato, which was initially approved by the FDA in 2019 for use alongside an oral antidepressant, provides an innovative option for the nearly 30 percent of the approximately 280 million people worldwide diagnosed with major depressive disorder who experience treatment-resistant symptoms. According to Bill Martin, head of neuroscience at Johnson & Johnson, many patients endure long periods trying ineffective treatments, significantly affecting their emotional well-being and daily lives.
The application for expanded use is supported by data from a recent late-stage clinical trial, which demonstrated that Spravato could alleviate symptoms of depression as quickly as 24 hours after administration and maintain its effectiveness for at least a month. Administered as a nasal spray, Spravato requires supervision in a healthcare setting, distinguishing it from typical antidepressants that mainly target serotonin and dopamine. Instead, it enhances glutamate levels, a crucial neurotransmitter that facilitates communication between brain neurons.
Sales of Spravato have surged, reflecting a 60% increase in revenue to $271 million in the second quarter compared to the same period in the previous year. The drug has already reached approximately 100,000 patients across 77 countries, indicating a growing acceptance and recognition of its benefits in treating depression.
This hopeful development signifies an important step forward in mental health care, potentially improving the lives of those who have struggled with ineffective treatments for depression. With continued advancements, the future looks promising for individuals seeking relief from their symptoms.